Marksans Pharma Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7hsz20ts09olxkebq6eokcz1.pdf

Key Takeaways


Teva Facility Acquisition & Capacity Expansion

Mark Saldanha: "With new capacity of that magnitude, and that volume, will definitely give tremendous potential for growth, and that's where we are, you have to invest today to see returns tomorrow..."

Margin Dynamics & Cost Environment

Mark Saldanha: "No one has a crystal ball to see as to what impact it will have. Obviously, China has got its own challenges of lockdown. So again, we are very cautious in terms of giving any forward-looking statement, but as of today, it is looking positive, it is improving to that level."

US Market: Pricing, Penetration & Pipeline

Mark Saldanha: "Well, obviously, it's just at the tip of the iceberg, we have not penetrated anything significantly, but we are still doing decent numbers."

UK & Other International Markets

Mark Saldanha: "I think outlook is only going to get stronger, because of the product pipeline that we have and the nature of the products that are getting approved."

Product Mix, R&D & Strategic Initiatives

Mark Saldanha: "The only difference between OTC and Rx, is Rx, the distribution channel has consolidated tremendously, and that consolidation has affected competition and price erosion, which has taken place as a cascading impact of that, while OTC is still fragmented and diversified, where that is concerned."

M&A & Europe Expansion

Mark Saldanha: "It's difficult to say because we don't have a target right now in hand, so it's difficult to actually put a potential target."

Guidance & Commitments

CommitmentSpecificsTimeline
Teva acquisition closeTransaction finalized, subject to closing conditionsApril 1, 2023
Teva capacity rampScale to 400 crore units (first objective), then 800 crore unitsOver the next two years
Teva total investment₹200 crores (acquisition + Capex), funded via internal accrualsSpread over next two years
First API DMF filingFile a couple of DMFs for captive consumption moleculesMid-2023
API profitability upsideCost advantage and margin improvement from backward integrationEnd of 2023 or early 2024
US ANDA approvals~5 approvals expectedCalendar year 2023
US awarded items commercializationAwarded items planned for launchBy March 2023
Revenue milestoneCross ₹2,000 croresNext financial year (FY24)
Revenue milestoneReach ₹3,000 crores within 1/3rd the time taken to go from ₹1,000 to ₹2,000 croresAfter crossing ₹2,000 crores
Emerging markets revenueDouble revenueNext couple of years
R&D spend targetIncrease to 4–5% of salesComing years
EBITDA margin20% number visible if input cost and freight reduction trend continuesNext year

Key Metrics

MetricQ2 FY23
Operating revenue₹452.6 cr, +25.5% YoY
US & North America revenue₹190.3 cr, +13.7% YoY
EU & UK formulation revenue₹193.5 cr, +32.6% YoY
Australia & New Zealand revenue₹43.9 cr, +39% YoY
Rest of world revenue₹24.9 cr, +56.4% YoY
Gross margin50.7%, declined 80 bps YoY from 51.4%
EBITDA₹80.3 cr, +33.6% YoY
EBITDA margin17.7%, improved 110 bps YoY from 16.6%
Profit after tax₹60.1 cr, +29.9% YoY
EPS₹1.52, +36.3% YoY
R&D expense (H1 FY23)₹18.7 cr, 2.1% of sales
Cash and bank balance₹335 cr as of 30 September 2022
Global OTC/Rx mix65% OTC, 35% Rx; historically 50-50
ANDA approvals expected in 2023~5, then 7–8 per year average
FY23 revenue trending₹1,800 cr